Brief: Inventiva Announces Positive Topline Results From The Investigator-Initiated Phase II Clinical Trial Evaluating Lanifibranor In Patients With T2D And NAFLD
13/06/2023 22:03
June 13 (Reuters) - Inventiva Sa IVAA.PA :
* INVENTIVA ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE
INVESTIGATOR-INITIATED PHASE II CLINICAL TRIAL EVALUATING
LANIFIBRANOR IN PATIENTS WITH T2D AND NAFLD
* STUDY CONFIRMED FAVORABLE SAFETY AND TOLERABILITY PROFILE
OF
LANIFIBRANOR
* INVENTIVA - LANIFIBRANOR 800MG ACHIEVED PRIMARY EFFICACY
ENDPOINT
* INVENTIVA - SIGNIFICANTLY HIGHER PROPORTION OF PATIENTS
ACHIEVED
GREATER THAN 30% LIVER TRIGLYCERIDE REDUCTION
* SIGNIFICANTLY HIGHER PROPORTION OF PATIENTS ACHIEVED NAFLD
RESOLUTION WITH LANIFIBRANOR COMPARED TO PLACEBO
Source text for Eikon: ID:nGNE81VCmb
Further company coverage: IVAA.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inventiva SA
See all newsFrance's Inventiva H1 net loss narrows
Brief: Euronext Includes Genfit, Inventiva In SBF120 Index; Interparfums, Verallia Excluded
Brief: Inventiva Announces Last Patient Visit In Nativ3 Phase 3 Clinical Trial Of Lanifibranor In Mash
Brief: Inventiva Announces Comprehensive Capital Structure Optimization Including Debt And Equity Financing In Advance Of The Anticipated Phase 3 Readout
Brief: Inventiva Secures Up To €150 Mln Debt Financing, Extends Debt Maturity To 2030